Mersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Sells $10,972.08 in Stock

Mersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal sold 5,598 shares of Mersana Therapeutics stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $1.96, for a total value of $10,972.08. Following the sale, the senior vice president now owns 63,716 shares in the company, valued at $124,883.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Mersana Therapeutics Stock Down 5.5 %

MRSN opened at $1.88 on Thursday. The company has a debt-to-equity ratio of 2.02, a current ratio of 2.72 and a quick ratio of 2.72. Mersana Therapeutics, Inc. has a 12 month low of $1.07 and a 12 month high of $6.28. The stock has a market capitalization of $230.04 million, a P/E ratio of -1.65 and a beta of 1.49. The business has a 50 day simple moving average of $1.68 and a 200-day simple moving average of $2.37.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $8.72 million. Mersana Therapeutics had a negative return on equity of 333.91% and a negative net margin of 349.98%. Mersana Therapeutics’s revenue for the quarter was down 78.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. On average, equities analysts anticipate that Mersana Therapeutics, Inc. will post -0.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MRSN has been the topic of a number of research reports. Lifesci Capital upgraded Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Citigroup dropped their price target on Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Finally, Robert W. Baird dropped their price target on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Mersana Therapeutics has an average rating of “Moderate Buy” and an average target price of $6.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC purchased a new position in Mersana Therapeutics in the 2nd quarter valued at approximately $90,000. Susquehanna Fundamental Investments LLC raised its stake in shares of Mersana Therapeutics by 31.9% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 308,691 shares of the company’s stock worth $620,000 after buying an additional 74,575 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Mersana Therapeutics in the 2nd quarter worth about $508,000. Marshall Wace LLP grew its stake in Mersana Therapeutics by 358.0% in the 2nd quarter. Marshall Wace LLP now owns 176,029 shares of the company’s stock valued at $354,000 after acquiring an additional 137,596 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Mersana Therapeutics by 262.1% during the 2nd quarter. XTX Topco Ltd now owns 121,432 shares of the company’s stock valued at $244,000 after acquiring an additional 87,893 shares in the last quarter. 93.92% of the stock is owned by hedge funds and other institutional investors.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.